Badran Mohamed M, Alsubaie Areej, Salem Bekhit Mounir M, Alomrani Abdullah H, Almomen Aliyah, Ibrahim Mohamed Abbas, Alshora Doaa Hasan
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia.
Saudi Pharm J. 2024 Dec;32(12):102208. doi: 10.1016/j.jsps.2024.102208. Epub 2024 Nov 22.
Itraconazole (ITZ) is a highly effective antifungal agent. However, its oral application is associated with systemic toxicity and poor topical use. The present study aims to improve the antifungal activity of ITZ by loading it into bioadhesive niosomes. This approach is considered to enhance the ocular permeation of ITZ, thereby boosting its efficacy against fungal infections. Therefore, it was encapsulated into niosomes (F1) and subsequently coated with hyaluronic acid (HA; F2), chitosan (CS; F3), or a bilayer of CS/HA (F4). In addition, they were further incorporated into pH-sensitive gels. This dual approach is expected to increase the amount of corneal-permeated ITZ, facilitating more effective management of ocular fungal infection. Firstly, the niosomes were prepared by hydrating proniosomes using span 60, cholesterol, and phospholipid. ITZ-niosomes showed an increase in vesicle size from 165.5 ± 3.4 (F1) to 378.2 ± 7.2 nm (F3). The zeta potential varied within -20.9 ± 2.1 (F1), -29.5 ± 3.1 (F2), 32.3 ± 1.9 (F3), and 22.6 ± 1.3 mV (F4). The high EE% values ranged from 78.1 ± 2.2 % to 86.6 ± 2.9 %. Regarding ITZ release, F1 demonstrated a high release profile, whereas bioadhesive niosomes showed sustained release patterns. Furthermore, gels containing niosomes displayed excellent gelling capacity and viscosity. Remarkably, F3 laden- gels (F3-ISG) demonstrated the highest corneal permeability of ITZ and antifungal activity with a safety effect. These results indicate that F3-ISG presents a promising strategy for boosting the ocular delivery of ITZ, that could help in treating ocular fungal infections.
伊曲康唑(ITZ)是一种高效抗真菌剂。然而,其口服应用存在全身毒性且局部使用效果不佳。本研究旨在通过将ITZ载入生物黏附性脂质体来提高其抗真菌活性。这种方法被认为可增强ITZ的眼部渗透,从而提高其对真菌感染的疗效。因此,将其包封于脂质体(F1)中,随后用透明质酸(HA;F2)、壳聚糖(CS;F3)或CS/HA双层(F4)进行包衣。此外,将它们进一步掺入pH敏感凝胶中。这种双重方法有望增加角膜渗透的ITZ量,便于更有效地治疗眼部真菌感染。首先,使用司盘60、胆固醇和磷脂对前体脂质体进行水化来制备脂质体。ITZ脂质体的囊泡大小从165.5±3.4(F1)增加到378.2±7.2nm(F3)。ζ电位在-20.9±2.1(F1)、-29.5±3.1(F2)、32.3±1.9(F3)和22.6±1.3mV(F4)范围内变化。高包封率(EE%)值在78.1±2.2%至86.6±2.9%之间。关于ITZ释放,F1呈现高释放曲线,而生物黏附性脂质体显示出缓释模式。此外,含脂质体的凝胶表现出优异的胶凝能力和粘度。值得注意的是,含F3的凝胶(F3-ISG)显示出ITZ最高的角膜渗透率和抗真菌活性且具有安全效应。这些结果表明,F3-ISG为促进ITZ的眼部递送提供了一种有前景的策略,有助于治疗眼部真菌感染。